Qiagen (NYSE:QGEN)‘s stock had its “neutral” rating restated by stock analysts at Jefferies Financial Group in a research note issued on Monday.
A number of other equities analysts also recently issued reports on QGEN. Commerzbank reissued a “buy” rating on shares of Qiagen in a report on Monday, September 17th. Deutsche Bank set a $44.00 price objective on shares of Qiagen and gave the stock a “buy” rating in a report on Friday, October 5th. BidaskClub downgraded shares of Qiagen from a “sell” rating to a “strong sell” rating in a report on Thursday, October 11th. Morgan Stanley raised their price objective on shares of Qiagen from $38.00 to $39.00 and gave the stock an “overweight” rating in a report on Wednesday, October 10th. Finally, Barclays reaffirmed a “buy” rating on shares of Qiagen in a report on Tuesday, October 30th. Seven investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $40.67.
Shares of NYSE QGEN opened at $36.48 on Monday. The company has a current ratio of 1.37, a quick ratio of 1.25 and a debt-to-equity ratio of 0.42. The stock has a market cap of $8.26 billion, a PE ratio of 28.72, a P/E/G ratio of 2.16 and a beta of 0.92. Qiagen has a 52-week low of $31.01 and a 52-week high of $39.45.
Qiagen (NYSE:QGEN) last announced its quarterly earnings results on Monday, October 29th. The company reported $0.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.33 by $0.02. The firm had revenue of $377.91 million for the quarter, compared to the consensus estimate of $382.16 million. Qiagen had a net margin of 6.00% and a return on equity of 12.52%. On average, equities research analysts forecast that Qiagen will post 1.33 earnings per share for the current fiscal year.
A number of large investors have recently modified their holdings of QGEN. Vanguard Group Inc raised its position in shares of Qiagen by 2.0% during the third quarter. Vanguard Group Inc now owns 6,627,163 shares of the company’s stock valued at $251,037,000 after buying an additional 128,125 shares during the last quarter. Morgan Stanley raised its position in shares of Qiagen by 16.3% during the third quarter. Morgan Stanley now owns 1,468,052 shares of the company’s stock valued at $55,611,000 after buying an additional 205,698 shares during the last quarter. Finally, State of Alaska Department of Revenue raised its position in shares of Qiagen by 2.0% during the fourth quarter. State of Alaska Department of Revenue now owns 23,547 shares of the company’s stock valued at $811,000 after buying an additional 463 shares during the last quarter. 62.73% of the stock is currently owned by institutional investors and hedge funds.
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.
Further Reading: What are the most popular ETFs
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.